Last reviewed · How we verify
Lateral femoral cutaneous nerve block
Lateral femoral cutaneous nerve block is a Small molecule drug developed by Kafrelsheikh University. It is currently in Phase 1 development. Also known as: Bupivacaine 0.5%.
At a glance
| Generic name | Lateral femoral cutaneous nerve block |
|---|---|
| Also known as | Bupivacaine 0.5% |
| Sponsor | Kafrelsheikh University |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
- Itching
- Nausea
- Vomiting
- Leg Swelling
- Incisional Numbness
- Prolonged numbness from spinal
- Rash, shingles
- Post-Operative Fall
- Lower extremity sensitivity
Key clinical trials
- Pericapsular Nerve Group (PENG) Block Combined With Lateral Femoral Cutaneous Nerve (LFCN) Block or Wound Infiltration for Postoperative Analgesia in Anterior Approach Total Hip Arthroplasty: A Randomized Controlled Trial (NA)
- Local Infiltration Analgesia Versus Quadruple Nerve Blocks in Total Knee Arthroplasty. (NA)
- Comparison of Pericapsular Nerve Group+ Lateral Femoral Cutaneous Nerve Block Versus Lumbar Erector Spinae Plane Block in Hip Arthroplasty Surgery
- PENG Block vs Suprainguinal FICB vs Lumbar ESPB for Analgesia After Hip Surgery (NA)
- PENG vs L-ESPB With S-ESPB for Analgesia in Total Hip Arthroplasty (PHASE4)
- BiFeS vs. iPACK in Postoperative Knee Arthroplasty Analgesia (NA)
- Perioperative Analgesic Effects of PENG Versus PENG Plus LFCN Block in Hip Surgeries (NA)
- Peripheral Nerve Blocks for Above-the-knee Amputations (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Lateral femoral cutaneous nerve block CI brief — competitive landscape report
- Lateral femoral cutaneous nerve block updates RSS · CI watch RSS
- Kafrelsheikh University portfolio CI
Frequently asked questions about Lateral femoral cutaneous nerve block
What is Lateral femoral cutaneous nerve block?
Lateral femoral cutaneous nerve block is a Small molecule drug developed by Kafrelsheikh University.
Who makes Lateral femoral cutaneous nerve block?
Lateral femoral cutaneous nerve block is developed by Kafrelsheikh University (see full Kafrelsheikh University pipeline at /company/kafrelsheikh-university).
Is Lateral femoral cutaneous nerve block also known as anything else?
Lateral femoral cutaneous nerve block is also known as Bupivacaine 0.5%.
What development phase is Lateral femoral cutaneous nerve block in?
Lateral femoral cutaneous nerve block is in Phase 1.
What are the side effects of Lateral femoral cutaneous nerve block?
Common side effects of Lateral femoral cutaneous nerve block include Itching, Nausea, Vomiting, Leg Swelling, Incisional Numbness, Prolonged numbness from spinal.
Related
- Manufacturer: Kafrelsheikh University — full pipeline
- Also known as: Bupivacaine 0.5%
- Compare: Lateral femoral cutaneous nerve block vs similar drugs
- Pricing: Lateral femoral cutaneous nerve block cost, discount & access